Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in south Chinese patients

作者：Zhang, Dao-Yu; Yuan, Xiao-Qing; Yan, Han; Cao, Shan; Zhang, Wei; Li, Xiao-Lin; Zeng, Hui; Chen, Xiao-Ping^*

来源：Pharmacogenomics, 2016, 17(14): 1519-1531.

DOI：10.2217/pgs-2016-0084

• acute myeloid leukemia
• complete remission
• DCK
• prognosis
• SNP

Aim: DCK is a rate-limiting enzyme in cytarabine activation. rs4643786 and rs67437265 (P122S) variants are reported to affect DCK activity. Patients & methods: A total of 282 newly diagnosed acute myeloid leukemia (AML) patients were treated with cytarabine combined chemotherapy and genotyped for rs4643786 and rs67437265. Prognosis data were obtained through regular follow-up. DCK mRNA expression was detected in pretreatment blood or bone marrow mononuclear cells. Results: rs4643786 showed strong linkage disequilibrium with rs67437265. rs4643786 CT heterozygotes showed significantly higher complete remission rate (p = 0.028), superior overall survival (p = 0.006) and relapse-free survival (p = 0.020) than wildtype TT homozygotes. rs4643786 polymorphism was an independent predictor for AML prognosis. Conclusion: DCK rs4643786 may serve as an independent predictor of drug response and AML outcome.

• 出版日期2016-9
• 单位中南大学